Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 12 recruiting now early-phase tilt

Heart Disease: early-phase trial registry

12 of 34 indexed Heart Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #451 of 28,707 conditions by registered trial count.

34 US clinical trials · 12 currently recruiting · #451 of 28,707 conditions by registered trial count

Heart Disease: 34 US clinical trials tracked, 12 recruiting.

Heart Disease is the subject of 34 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Environmental Health Sciences (NIEHS), running 2 of these trials.

Enrollment posture brief

Registry condition heart-disease

OPEN 12 | RECR 35% | LATE 3 | EARLY 6 | RANK #451 | SPON 2

Nearest open-share peer: Arrhythmia (35% recruiting · 17 trials)

Erectile Dysfunction41.2%Heart Disease (this)35%Anatomic Stage IIIB Breast C32.4%Anatomic Stage IIA Breast Ca26.5%Dry Eye Disease14.7%
Open-enrollment share among volume-matched conditions near Heart Disease

Heart Disease lists 12 open slots (35% of 34 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Heart Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Heart Disease is recruiting below its size-band peers.

    12 of 34 indexed trials (35.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Heart Disease trials is spread across many organizations.

    National Institute of Environmental Health Sciences (NIEHS) accounts for 2 of 34 trials (5.9%). 30 distinct sponsors appear on at least one study for this condition label.

  3. Typical Heart Disease enrolment sits around 290 participants.

    Median target enrolment is 290 among the 32 trials that report a genuine target (sentinel values excluded). 7 of those (21.9%) plan for fewer than 100 participants.

  4. Heart Disease splits between interventional and observational designs.

    19 interventional and 15 observational studies make up this index (55.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 22Phase 32Phase 41

Open and recent trials

34 total, page 1 of 1

RECRUITING 25,000 participants

Personalized Environment and Genes Study

National Institute of Environmental Health Sciences (NIEHS)

NCT00341237

RECRUITING 3,000 participants

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

Texas A&M University

NCT06726590

RECRUITING 750 participants

Cooperative Assessment of Late Effects for SCD Curative Therapies

Vanderbilt University Medical Center

NCT05153967

RECRUITING NA 634 participants

Heart Disease of the Small Arteries in Women and Men

Cedars-Sinai Medical Center

NCT00573027

RECRUITING NA 368 participants

Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)

Oregon Health and Science University

NCT06629610

RECRUITING 300 participants

Using CTA Measures to Define Cardiac Risk In NFL Alumni

HeartFlow

NCT06831409

RECRUITING NA 290 participants

Promoting Physical Activity and Fitness Among Underserved Latino Families Living in U.S.-Mexico Border Regions

San Diego State University

NCT06596902

RECRUITING Phase 2 240 participants

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Abcentra

NCT06927739

RECRUITING NA 150 participants

Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)

Lancaster General Hospital

NCT06688396

RECRUITING 150 participants

Sex Differences in Barriers and Participation in Physical Activity During and Following Cardiac Rehabilitation

Duke University

NCT07214350

RECRUITING NA 120 participants

Healthy Living Anson Study

University of North Carolina, Chapel Hill

NCT07126587

RECRUITING 80 participants

Studies of Neuregulin/ERBB Signaling in Human Heart

Douglas B. Sawyer

NCT02820233

ACTIVE NOT RECRUITING 19,114 participants

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

Anne Murray

NCT07224347

ACTIVE NOT RECRUITING NA 300 participants

NYUCI-ES: Psychosocial Intervention to Improve Health Outcomes for Chinese and Korean ADRD Caregivers

New York University

NCT05461495

ACTIVE NOT RECRUITING 105 participants

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

Johns Hopkins University

NCT02694094

COMPLETED 9,000 participants

Environmental Polymorphisms Registry Health and Exposures Survey

National Institute of Environmental Health Sciences (NIEHS)

NCT01688986

COMPLETED 800 participants

Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY

XDx

NCT00761787

COMPLETED NA 647 participants

The CREATE Wellness Study

Kaiser Permanente

NCT02302612

COMPLETED Phase 4 390 participants

Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

The University of Texas Health Science Center, Houston

NCT00178620

COMPLETED NA 348 participants

A Helping Hand Among Low-Income Patients

University of Southern California

NCT02147522

COMPLETED 310 participants

Family Genetics Health Education and Healthy Behaviors

National Human Genome Research Institute (NHGRI)

NCT01498276

COMPLETED Phase 3 309 participants

The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.

Wake Forest University Health Sciences

NCT03097120

COMPLETED Phase 1 280 participants

A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)

Children's Hospital Medical Center, Cincinnati

NCT02250820

COMPLETED Phase 3 245 participants

Communicating Smoking Risks Through Graphic Warning Labels

University of Pennsylvania

NCT01782053

COMPLETED NA 194 participants

Strong Hearts: Rural CVD Prevention

Cornell University

NCT02499731

COMPLETED Phase 1 120 participants

Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil

Cardiovascular Research Associates

NCT00988585

COMPLETED 51 participants

Initial Experience With the AngioVac Venous Drainage Cannula

Angiodynamics

NCT02775565

COMPLETED 49 participants

Comparison Endotracheal Cardiac Output Monitor (ECOM) to a Standard Device in Measuring Heart Blood Volume

University of California, Los Angeles

NCT00883857

COMPLETED Phase 2 29 participants

Beating the Blues for Your Heart

Indiana University

NCT01605552

COMPLETED NA 26 participants

NUTRITION MATTERS: A Food is Medicine Intervention for African-American Adults With Multiple Chronic Conditions

Winston Salem State University

NCT06933940

COMPLETED Phase 1 21 participants

Sildenafil in Single Ventricle Patients

Duke University

NCT01169519

COMPLETED Phase 1 18 participants

Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children

Children's Hospital Medical Center, Cincinnati

NCT02836431

COMPLETED

Screening for Inherited Heart Disease

National Heart, Lung, and Blood Institute (NHLBI)

NCT00001746

COMPLETED

Outpatient Evaluation of Patients With Known or Suspected Heart Disease

National Heart, Lung, and Blood Institute (NHLBI)

NCT00001400

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Heart Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Nasal Placebo Other
1 trials
Pentobarbital Drug
1 trials
Self-care management Behavioral
1 trials
Sildenafil by injection Drug
1 trials
Usual Care Control Other
1 trials
CREATE Wellness Behavioral
1 trials
AngioVac Device
1 trials
Dexmedetomidine 1mcg Intravenous Drug
1 trials

US sites by state

Facility locations filed on Heart Disease trials. A trial with sites in several states counts in each.

North Carolina 8 trials
California 7 trials
Maryland 6 trials
Texas 4 trials
Pennsylvania 3 trials
Ohio 3 trials
New York 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Heart Disease page

34 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Heart Disease condition card totals 34 registered trials; most-linked intervention Nasal Placebo; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.